Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Enhertu Shows 14.3-Month PFS in HER2+ Lung Cancer Trial
3+ hour, 10+ min ago (338+ words) Results were presented today during the Presidential Symposium at the IASLC 2026 World Conference on Lung Cancer (#WCLC26) hosted by the International Association for the Study of Lung Cancer in Seoul, South Korea (abstract #PL03.08). In the primary endpoint of PFS, Enhertu monotherapy…...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
4+ hour, 55+ min ago (1000+ words) AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial in this setting Results were presented today during the Presidential Symposium at the IASLC 2026 World Conference on…...
TAGRISSO?? (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
4+ hour, 11+ min ago (605+ words) Longest survival data ever reported in a global Phase III trial in this setting New data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages These results were presented today during the Presidential…...
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
25+ min ago (1324+ words) Statistics cookies help us to understand how visitors interact with websites by collecting and reporting information anonymously. Marketing cookies allow us to display more relevant ads that are engaging for our users and thereby, they are more valuable for publishers…...
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
6+ hour, 47+ min ago (1584+ words) Daiichi Sankyo and AstraZeneca's Enhertu is the first HER2 directed medicine to delay disease progression over standard of care in a phase 3 trial in this setting Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo…...
personalised cancer vaccine all news related to
8+ hour, 33+ min ago (67+ words) Nation Thailand TAGS "personalised cancer vaccine" All News personalised cancer vaccine In Focus personalised cancer vaccine BreakingNews of personalised cancer vaccine Your Interested Follow Story personalised cancer vaccine GPO reports personalised cancer vaccine use in two patients A Thai personalised…...
Vail Williams appoints valuation partner
14+ hour, 13+ min ago (442+ words) You can review how this information is used and customise your consent preferences for cookies or for any other identifying technology below by either purpose, feature or third party vendor. Certain vendors may process personal data on the basis of…...
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial (SMMT:NASDAQ)
15+ hour, 9+ min ago (64+ words) Seeking Alpha nopparit/iStock via Getty Images Summit Therapeutics (SMMT) on Sunday said ivonescimab significantly extended survival compared with Merck’s (MRK) Keytruda in a late-stage lung cancer trial conducted by its partner Akeso (AKESF) in China. Ivonescimab reduced the risk…...
Professor Jie Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, China.
1+ day, 5+ hour ago (72+ words) EurekAlert! Professor Jie Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, China. More on this News Release Phase III ARTEMIS-008 trial shows risvutatug rezetecan significantly improves…...
WCLC26: GSK's ris-rez cuts death risk 54% in China Phase III lung cancer trial
17+ hour, 30+ min ago (16+ words) FirstWord Pharma...